| Literature DB >> 27006679 |
Yan-Song Liu1, Marcus Gadau2, Guo-Xue Zhang1, Hao Liu1, Fu-Chun Wang1, Christopher Zaslawski3, Tie Li1, Yuan-Sheng Tan4, Christine Berle3, Wei-Hong Li3, Sergio Bangrazi5, Stefano Liguori5, Shi-Ping Zhang2.
Abstract
In planning for a large-scale multicenter trial to evaluate the effect of acupuncture for the treatment of lateral elbow pain, a pilot study was conducted. This was a prospective, investigator- and patient-blinded, nonrandomized, placebo controlled trial. Subjects were evaluated at baseline, before fourth, seventh, and ninth treatment, and at a two-week posttreatment follow-up. The treatment group received unilateral acupuncture at LI 10 and LI 11 at the affected side with manual needle manipulation; the control group received sham-laser acupuncture at the same acupoints. Measures included (i) disabilities of the arm, shoulder, and hand (DASH) questionnaire, (ii) pain-free grip strength (PFGS), and (iii) a visual analogue scale (VAS) for pain. Significant differences in DASH score, PFGS, and VAS between treatment and control group were found at the ninth treatment (n = 20 for each group, P < 0.05). Only DASH showed significant differences compared to the control for all the measurement time points after treatment commenced and appears to be a sensitive and appropriate primary outcome measure for the future multisite trial. Results from this pilot study provided relevant information about treatment efficacy, credibility of control treatment, and sensitivity of different outcome measures for the planning of the future trial.Entities:
Year: 2016 PMID: 27006679 PMCID: PMC4783565 DOI: 10.1155/2016/8182071
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Flow chart trial participants.
Demographic data.
| Treatment group | Control group | |
|---|---|---|
| Male (%) | 11 (55) | 8 (40) |
| Female (%) | 9 (45) | 12 (60) |
| Total | 20 | 20 |
| Age (mean ± SD) | 42 ± 16.68 | 50.65 ± 7.27 |
| Duration of condition (mean ± SD) | 7.45 ± 6.09 | 9.45 ± 3.49 |
| DASH (mean ± SD) | 26.03 ± 7.61 | 21.79 ± 11.56 |
| PFGS (mean ± SD) | 16.54 ± 7.29 | 19.12 ± 9.15 |
| VAS at rest (mean ± SD) | 2.34 ± 1.28 | 1.65 ± 1.16 |
| VAS in motion (mean ± SD) | 3.96 ± 1.42 | 4.03 ± 1.31 |
| VAS during exertion (mean ± SD) | 6.62 ± 1.72 | 7.25 ± 1.62 |
∗: P = 0.047, significant difference between treatment and control group.
Figure 2Credibility assessment comparing treatment and control interventions using a five-point rating scale (n = 20 for each group). Histograms display means, error bars show standard deviations (SD), and no significant difference between groups was found.
Within-group comparison between baseline and different time points (n = 20 for each group).
| Time point | DASH | PFGS | VAS at rest | VAS in motion | VAS in exertion | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Treatment group | Control group | Treatment group | Control group | Treatment group | Control group | Treatment group | Control group | Treatment group | Control group | ||
| Baseline | Median (min.–max.) | 24.58 (10.83–35.83) | 18.33 (9.17–43.33) | 16.55 (7.10–31.70) | 17.23 (8.02–38.57) | 2.55 (0.10–6.00) | 1.45 (0.00–4.30) | 3.65 (2.00–8.00) | 4.15 (1.60–6.70) | 6.70 (3.50–9.50) | 7.35 (3.20–10.00) |
|
| |||||||||||
| 4th treatment | Median (min.–max.) | 19.16 (10.82–34.17) | 16.66 (6.67–39.70) | 17.84 (8.30–32.90) | 16.50 (8.73–38.00) | 1.45 (0.00–4.70) | 1.05 (0.00–4.70) | 2.95 (0.00–6.70) | 3.20 (1.50–6.50) | 4.85 (2.00–8.50) | 6.35 (2.60–10.00) |
| Comparison to baseline ( | Median difference |
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||
| 7th treatment | Median (min.–max.) | 13.34 (8.33–24.17) | 17.08 (6.67–32.50) | 19.45 (11.20–34.50) | 17.48 (8.78–37.87) | 0.55 (0.00–3.40) | 0.90 (0.00–3.60) | 1.75 (0.20–6.30) | 2.90 (1.50–6.90) | 3.15 (0.80–7.40) | 6.20 (2.60–9.50) |
| Comparison to baseline ( | Median difference |
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||
| 9th treatment | Median (min.–max.) | 10.83 (6.67–21.67) | 17.08 (4.17–31.67) | 20.55 (12.50–35.60) | 18.81 (8.73–36.90) | 0.50 (0.00–2.10) | 0.95 (0.00–4.50) | 1.25 (0.00–4.10) | 2.60 (1.50–6.50) | 2.40 (0.80–7.00) | 5.80 (2.00–9.60) |
| Comparison to baseline ( | Median difference |
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||
| 2 weeks after treatment | Median (min.–max.) | 6.67 (2.50–21.67) | 15.83 (3.33–31.67) | 21.20 (12.00–37.50) | 16.46 (8.00–39.87) | 0.00 (0.00–2.70) | 0.90 (0.00–1.70) | 0.60 (0.00–3.40) | 2.70 (0.80–7.40) | 1.85 (0.30–8.40) | 5.25 (1.30–9.60) |
| Comparison to baseline ( | Median difference |
|
|
|
|
|
|
|
|
|
|
DASH score: disability of the arm, shoulder, and hand score; PFGS: pain-free grip strength; VAS: visual analogue scale. ∗: statistically significant difference (P < 0.05) between medians.
Figure 3DASH and PFGS changes over time. Line graphs showing changes of the two groups from baseline throughout the trial period for (a) disabilities of the arm, shoulder, and hand (DASH) score (functional impairment) and (b) pain-free grip strength (PFGS) (n = 20 for each group). Error bars show standard deviations (SD); ∗: statistically significant difference (P < 0.05) between the two groups at a given time point. (c1)–(c3) VAS changes over time. Line graphs showing changes of the two groups from baseline throughout the trial period for (c1) pain at rest, (c2) pain in motion, and (c3) pain during exertion on visual analogue scales (VAS) (n = 20 for each group). Error bars show standard deviations (SD); ∗: statistically significant difference (P < 0.05) between the two groups at a given time point.